212 related articles for article (PubMed ID: 28071636)
1. Epidemiology of male seminomatous and nonseminomatous germ cell tumors and response to first-line chemotherapy from a tertiary cancer center in India.
Joshi A; Zanwar S; Shetty N; Patil V; Noronha V; Bakshi G; Prakash G; Menon S; Prabhash K
Indian J Cancer; 2016; 53(2):313-316. PubMed ID: 28071636
[TBL] [Abstract][Full Text] [Related]
2. Current management of stage I testicular germ cell tumors in a French cancer institute. A practice analysis over the 10 past years.
Chanal E; Bouleftour W; Guillot A; Rowinski E; Bernichon E; Tremeau L; Lardon R; Lacroix B; Lorin S; Delorme G; Perraud Y; Armand C; Levigne F; Vallard A; Langrand-Escure J; Fournel P; Benoite M; Vassal C
Bull Cancer; 2019 Dec; 106(12):1086-1093. PubMed ID: 31582176
[TBL] [Abstract][Full Text] [Related]
3. Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis.
Ramani VA; Grey BR; Addla SK; Dunham MP; Sangar VK; Clarke NW
Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):247-52. PubMed ID: 18093814
[TBL] [Abstract][Full Text] [Related]
4. Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group.
Bamias A; Aravantinos G; Kastriotis I; Alivizatos G; Anastasiou I; Christodoulou C; Gyftaki R; Kalofonos HP; Dimopoulos MA
Urol Oncol; 2011; 29(2):189-93. PubMed ID: 19362863
[TBL] [Abstract][Full Text] [Related]
5. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion.
Lago-Hernandez CA; Feldman H; O'Donnell E; Mahal BA; Perez V; Howard S; Rosenthal M; Cheng SC; Nguyen PL; Beard C; D'Amico AV; Sweeney CJ
Ann Oncol; 2015 Jul; 26(7):1396-401. PubMed ID: 25888612
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors.
Horwich A; Dearnaley DP; Nicholls J; Jay G; Mason M; Harland S; Peckham MJ; Hendry WF
J Clin Oncol; 1991 Jan; 9(1):62-9. PubMed ID: 1702147
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
Haugnes HS; Laurell A; Stierner U; Bremnes RM; Dahl O; Cavallin-Ståhl E; Cohn-Cedermark G
Acta Oncol; 2012 Feb; 51(2):168-76. PubMed ID: 22175254
[TBL] [Abstract][Full Text] [Related]
10. Factors that impact the outcomes in testicular germ cell tumors in low-middle-income countries.
Saju SV; Radhakrishnan V; Ganesan TS; Dhanushkodi M; Raja A; Selvaluxmy G; Sagar TG
Med Oncol; 2019 Feb; 36(3):28. PubMed ID: 30725328
[TBL] [Abstract][Full Text] [Related]
11. Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols.
Tandstad T; Solberg A; Håkansson U; Stahl O; Haugnes HS; Oldenburg J; Dahl O; Kjellman A; Angelsen A; Cohn-Cedermark G;
Acta Oncol; 2015 Apr; 54(4):493-9. PubMed ID: 25192551
[TBL] [Abstract][Full Text] [Related]
12. Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy.
Gilbert DC; Norman AR; Nicholl J; Dearnaley DP; Horwich A; Huddart RA
BJU Int; 2006 Jul; 98(1):67-9. PubMed ID: 16831145
[TBL] [Abstract][Full Text] [Related]
13. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).
Culine S; Kerbrat P; Kramar A; Théodore C; Chevreau C; Geoffrois L; Bui NB; Pény J; Caty A; Delva R; Biron P; Fizazi K; Bouzy J; Droz JP;
Ann Oncol; 2007 May; 18(5):917-24. PubMed ID: 17351252
[TBL] [Abstract][Full Text] [Related]
14. [Observation policy for residual masses after chemotherapy for gonadal and extra-gonadal germ cell tumors].
Takizawa A; Miura T; Fujinami K; Osada Y
Hinyokika Kiyo; 2005 Apr; 51(4):247-51. PubMed ID: 15912783
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
17. Disease Characteristics and Treatment Outcome of Testicular Germ Cell Tumors Treated with Platinum-Based Regimens.
Sattar A; Masood M; Nisar H; Fatima I; Shahid AB
J Coll Physicians Surg Pak; 2018 Apr; 28(4):292-296. PubMed ID: 29615170
[TBL] [Abstract][Full Text] [Related]
18. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
[TBL] [Abstract][Full Text] [Related]
19. Histologic type, staging, and distribution of germ cell tumors in Korean adults.
Park DS; Chung MK; Chung JI; Ahn HJ; Lee ES; Choi HY; Yoon DK; Cheon J; Hong SJ; Lee YG; Yoon SM; Kim WJ; Kim HJ; Ryu SB; Ro JY
Urol Oncol; 2008; 26(6):590-4. PubMed ID: 18367106
[TBL] [Abstract][Full Text] [Related]
20. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]